Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in Patients with Severe Falciparum Malaria — Tran Tinh Hien (2004) | RDL Network
Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in Patients with Severe Falciparum Malaria
Antimicrobial Agents and Chemotherapy 48(11): 4234-4239
Article 2004 English
Authors
TH
Tran Tinh Hien
TD
Timothy M. E. Davis
LC
Ly Van Chuong
Abstract
1 min read
The first-dose pharmacokinetic properties of intramuscular (i.m.) artesunate (ARTS; 2.4 mg/kg immediately [stat], followed by 1.2 mg/kg i.m. daily) and artemether (ARM; 3.2 mg/kg i.m. stat, followed by 1.6 mg/kg i.m. daily) were compared in Vietnamese adults with severe falciparum malaria. A total of 19 patients were studied; 9 received ARTS, and 10 received ARM. ARTS was absorbed very rapidly; concentrations in plasma peaked between 1,362 and 8,388 nmol/liter (median, 5,710 nmol/liter) within 20 min of injection and then declined with a median (range) half-life (t(1/2)) of 30 (3 to 67) min. ARTS was hydrolyzed rapidly and completely to the biologically active metabolite dihydroartemisinin (DHA). Peak DHA concentrations in plasma ranged between 1,718 and 7,080 nmol/liter (median, 3,060 nmol/liter) and declined with a t(1/2) of 52 (26 to 69) min. In contrast, ARM was slowly and erratically absorbed. The absorption profile appeared biphasic. Maximum ARM concentrations in plasma ranged between 67 nmol/liter (a value close to the 50% inhibitory concentration for some Plasmodium falciparum isolates) and 1,631 nmol/liter (median, 574 nmol/liter) and occurred at a median (range) of 10 (1.5 to 24) h. There was relatively little conversion to DHA. After i.m. injection in cases of severe malaria, absorption of the water-soluble ARTS is rapid and extensive, whereas the oil-based ARM is slowly and erratically absorbed, with relatively little conversion to the more active DHA. On the basis of this pharmacological study, parenteral ARTS is preferable to ARM as an initial antimalarial therapy, particularly in the most seriously ill patients. These findings should be formally assessed by a randomized clinical trial.
Kamolrat Silamut, Paul N. Newton, Paktiya Teja‐Isavadharm, Yupin Suputtamongkol, Duangsuda Siriyanonda, Maneerat Rasameesoraj, Sasithon Pukrittayakamee, Sir Nicholas White
J. A. Simpson, Tsiri Agbenyega, Karen I. Barnes, Gianni Di Perri, Peter I. Folb, Melba Gomes, Sanjeev Krishna, Srivicha Krudsood, Sornchai Looareesuwan, Sharif Mahsufi Mansor, Helen McIlleron, Raymond Miller, Malcolm E. Molyneux, James Mwenechanya, Visweswaran Navaratnam, François Nosten, Piero Olliaro, Lorrin Pang, Isabela Ribeiro, Madalitso Tembo, Michèle van Vugt, Stephen A. Ward, K Weerasuriya,
ICE Hendriksen, George Mtove, Alison Kent, Samwel Gesase, Hugh Reyburn, Martha M. Lemnge, Niklas Lindegårdh, Nicholas Day, Lorenz von Seidlein, Sir Nicholas White, Arjen M. Dondorp, Joel Tärning
Discussion(0)
No comments yet. Be the first to comment.